Menu Search
Equities

Carisma Therapeutics Inc

W2J:DEU

Carisma Therapeutics Inc

Actions
  • Price (EUR)0.92
  • Today's Change-0.04 / -4.17%
  • Shares traded1.10k
  • 1 Year change-66.18%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Carisma Therapeutics Inc increased its cash reserves by 220.76%, or 53.41m. Cash Flow from Investing totalled 72.41m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 81.18m for operations while cash generated from financing totalled 62.18m.
Cash flow per share-1.69
Price/Cash flow per share--
Book value per share0.0087
Tangible book value per share0.0087
More ▼

Balance sheet in USDView more

Carisma Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 1.85% of the market capitalization can be attributed to its 77.61m and debt could be paid in full if management chose.
Current ratio3.25
Quick ratio--
Total debt/total equity4.96
Total debt/total capital0.8322
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.